When humans encounter foreign pathogens, the body recognizes these substances and the innate immune system works to neutralize the invasive pathogen and rid the body of its presence.  Typically, this process occurs in a relatively short period of time.  The innate immune system recognizes generic classes of molecules produced by a variety of disease-causing agents and pathogens.  When the innate immune system detects such foreign molecules, an inflammatory response is triggered in which certain cells attempt to isolate the invader and halt its spread.  The activity of these cells precipitates the redness and swelling at the site of injuries, and accounts for the fever, body aches, and flu-like symptoms, which accompany many types of infections. Toll-like receptors “TLRs”, as a family of ten cell surface and cytosolic receptors, recognize bacterial antigens and are the backbone of the innate immune system. If the TLRs fail, the entire immune system fails, leaving a person open to infection.  Additionally, if the TLRs are over-stimulated, they can induce disorders marked by chronic inflammation such as arthritis, lupus, and even cardiovascular disease. The Company recognized that TLRs are the first line of defense against a foreign pathogen.  When these molecules stimulate immune response, there is a tremendous effort both in killing viruses, combating, and even eliminating certain cancers.  MultiCell is using its TLR and T-cell targeting technologies to study how drug candidates modulate the immune system, and suppress the pro-inflammatory response elements common in autoimmune disorders such as Type-1 diabetes and MS, or mobilize during an immune response due to bacterial or viral infections.